Looming competition from the east
29/11/19 -"A number of initiatives taken by the Chinese government to strengthen its pharmaceutical sector have started to bear fruit – Biogene’s ‘zanubrutinib’ became the first innovative drug by a Chinese ..."
Pages
65
Language
English
Published on
29/11/19
You may also be interested by these reports :
19/06/26
Evaluating Pharma’s Defences
17/06/26
Our target price is reduced to CHF94 (from CHF97) on the back of a lower sales base. We have also adjusted forward years’ growth, slightly increasing ...
15/06/26
The target price is upgraded on the back of higher margins in 2026. The EBITDA margin is lifted from 15.4% to 17.9% for the full year (guidance is ...
09/06/26
Our estimates for 2026-2027 have been revised downward following the reclassification of Capsules & Health Ingredients (CHI) as discontinued ...